The purposes of this study were to quantify the impact of the duration of infusion and choice of stable isotope of glucose on measures of glucose rate of appearance (glucose R a ) and to determine whether the differences observed were due to tracer recycling via the glycogen pool (direct pathway) or gluconeogenesis (indirect pathway). Six healthy adult volunteers were studied on four occasions in the postabsorptive state during infusions of [1- 13 W e have previously demonstrated that during prolonged infusion, labeled leucine is presumably incorporated into protein and released into the vascular space, leading to an underestimation of leucine flux (1). Both carbon-and hydrogen-labeled glucose can potentially be recycled as the result of direct uptake of labeled glucose into and release from glycogen. Only carbon-labeled glucose, however, can potentially recycle via gluconeogenesis from labeled pools of lactate and pyruvate (2). Independent of whether tracer recycling occurs, duration of an isotope infusion may also affect the calculated glucose rate of appearance (R a ) if the tracer and tracee are not in nearly complete equilibrium. In normal subjects, the estimate of hepatic glucose production using a 2-h primed constant rate infusion of [6, H 2 ]glucose was significantly higher than that obtained after a primed 4-h isotope infusion (3). However, it was not clear from these studies whether this reduction was due to a difference in steady state or to a real physiological reduction in glucose R a over time. Kalhan et al. (2) measured glucose production in newborn infants who received a simultaneous infusion of [1-
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e have previously demonstrated that during prolonged infusion, labeled leucine is presumably incorporated into protein and released into the vascular space, leading to an underestimation of leucine flux (1) . Both carbon-and hydrogen-labeled glucose can potentially be recycled as the result of direct uptake of labeled glucose into and release from glycogen. Only carbon-labeled glucose, however, can potentially recycle via gluconeogenesis from labeled pools of lactate and pyruvate (2) . Independent of whether tracer recycling occurs, duration of an isotope infusion may also affect the calculated glucose rate of appearance (R a ) if the tracer and tracee are not in nearly complete equilibrium. In normal subjects, the estimate of hepatic glucose production using a 2-h primed constant rate infusion of [6, H 2 ]glucose was significantly higher than that obtained after a primed 4-h isotope infusion (3). However, it was not clear from these studies whether this reduction was due to a difference in steady state or to a real physiological reduction in glucose R a over time. Kalhan et al. (2) measured glucose production in newborn infants who received a simultaneous infusion of [1- 13 C]glucose and [6, H 2 ]glucose during a 2-h period. The glucose production rate measured from the dilution of [1- 13 C]glucose was slightly but significantly lower than that measured with the [6,6-2 H 2 ]glucose. The investigators concluded that this difference was due to recycling of the glucose C-1 through the Cori cycle.
Use of isotopes of glucose to estimate the R a and/or rate of production of glucose in humans is a fundamental research tool for the clinical investigator involved in studies of glucose homeostasis. Despite wide application of the isotope dilution techniques, the factors that affect the findings of such studies are incompletely understood. The purposes of the present study were to quantify the impact of the duration of infusion and choice of stable isotope tracer on tracer recycling. Using a dual isotope infusion approach, we assessed how these measures are affected by 1) potential recycling of labeled glucose molecules via gluconeogenesis and/or glycogenolysis and 2) the equilibration of the tracer with the tracee.
RESEARCH DESIGN AND METHODS
Subjects. The protocol was approved by the Institutional Review Board for Human Subject Research at Baylor College of Medicine in Houston, TX. Informed written consent was obtained from six healthy, male, nonobese adult volunteers: 28 Ϯ 2 years, BMI 23.7 Ϯ 1.2 kg/m 2 (mean Ϯ SE). The subjects had a normal physical examination and screening laboratory studies (complete blood count, electrolytes, renal and liver function tests), were taking no medications, and had no family history of diabetes. Each subject was studied on four occasions separated by 1-2 months. The order of studies A, B, and C was randomized. Study protocol D was carried out in all six subjects once the results of A, B, and C were available on the first three subjects. Experimental design. See Fig. 1 for graphic representation of protocols. Study protocol A. The subjects were instructed to consume a normal diet with a caloric distribution of 50% carbohydrate, 15% protein, and 35% fat during the week preceding the study. They were admitted to the Metabolic Research Unit at the Children's Nutrition Research Center in the afternoon and offered a standardized meal between 1730 and 1800 h. They were subsequently placed at bed rest and were fasted, with the exception of ad libitum water, until completion of study the following afternoon. Two intravenous catheters were introduced in each antecubital space under EMLA cream analgesia, one for isotope infusion and the other for blood sampling. A baseline blood sample was obtained before the initiation of isotope infusion.
At 0800 h, [ Isotope solutions were tested for sterility and pyrogenicity. The isotopes were dissolved in 0.45% saline, and the solution was filtered through a 0.2-m Millipore filter into sterile syringes. All sterile isotopes were prepared Ͻ48 h before study and maintained at 4°C until used. Separate solutions were prepared for each of the two tracers. Analyses. Blood samples were placed on ice, and the plasma was separated and kept at Ϫ70°C until assayed. Plasma glucose concentrations were determined by a glucose oxidase method (YSI glucose analyzer; YSI, Yellow Springs, OH), and plasma glucagon concentrations were determined by a commercial radioimmunoassay (Linco, St. Charles, MO). The penta-acetate derivative of glucose was prepared as described previously (4, 5) . The isotopic enrichments of [6, 6 2 H 2 ]glucose were measured by gas chromatography-mass spectrometry (GCMS) using a quadrupole instrument. The electron impact ionization fragments m/z 242-244 do not contain the carbon-1 of glucose, thus ensuring no interference from the [1-
13 C]glucose in the determination of the enrichment of [6,6-2 H 2 ]glucose. The contribution of 13 C randomized in other glucose carbons (C 2 -C 6 ) contributed Ͻ1% to the Mϩ2 enrichment after prolonged infusion of [1- 13 C]glucose. The isotopic enrichments of the [1-
13 C]glucose were measured by gas chromatography-combustion-isotope ratio mass spectrometry (Europa Scientific, ANCA-NT 2020, GC: HP 5890 with an HP 1701 column 30 m ϫ 0.25 mm ϫ 1 m; Agilent Technologies, Wilmington, DE). Finally, the acetyl-pentafluorobenzyl derivative of lactate was prepared as described previously (6, 7) . The 13 C enrichments in lactate were analyzed by negative chemical ionization GCMS as previously described (6,7). Calculations. Plasma glucose R a at steady state was calculated using established equations for isotope dilution (8,9):
where E i is the isotopic enrichment of the infusate, E p is the isotopic enrichment in plasma glucose, and I is the isotope infusion rate.
Regression analysis was used to calculate the rate constant (k) of the exponential curves representing enrichment decay of the [1-
13 C]glucose and [6,6-2 H 2 ]glucose tracers from the plasma pool during the 3 h after discontinuation of the isotope infusion. The enrichment values over time are described by the following equation:
where E 0 is the isotopic enrichment at steady state, and E t is isotopic enrichment at time t. The half-life (t 1/2 ) of each of the two isotopes was then calculated from equation 1, as follows:
The absolute amount of new tracer released from glycogen into the plasma pool (mmol/l) before and after administration of glucagon was calculated by multiplying the enrichment of the tracer (after subtracting the enrichment value obtained immediately before the glucagon bolus) by the glucose concentration.
Statistics. All values were expressed as mean Ϯ SE. ANOVA procedure for repeated measures (using Fisher's least squares difference for multiple comparisons) was used to test for differences in the mean glucose R a , glucose concentration, and the rate constant of isotope decay curve and t 1/2 values in the various subgroups under study. Differences in the lactate enrichment at the end of 14.5-vs. 2.5-h infusion of [1-
13 C]glucose were tested using paired Student's t test. P Յ 0.05 was considered to indicate statistical significance. All statistical analyses were performed on a personal computer with the statistical program SPSS (version 8.0) for Windows.
RESULTS
Plasma glucose concentrations. Plasma glucose concentrations at steady state were similar on all four study occasions (5.59 Ϯ 0.03, 5.34 Ϯ 0.02, 5.50 Ϯ 0.01, and 5.37 Ϯ 0.01 mmol/l for protocols A, B, C, and D, respectively; NS by ANOVA). After glucagon administration, glucose concentration increased to a similar degree in all protocols (⌬3.6 Ϯ 0.2, 3.3 Ϯ 0.3, 4.04 Ϯ 0.5, and 3.4 Ϯ 0.3 mmol/l in each of the protocols A, B, C, and D, respectively; NS). Plasma glucagon concentrations. Plasma glucagon con- centrations during the steady-state period were similar on all four study occasions (66 Ϯ 11, 62 Ϯ 5, 65 Ϯ 5, and 59 Ϯ 7 pg/ml for protocols A, B, C, and D, respectively; NS). After the intravenous administration of a glucagon bolus (1 mg), the plasma levels rose to Ͼ2,000 pg/ml in all four groups. Glucose isotopic enrichments and appearance rates. Isotopic enrichments during the steady-state period Ϫ0.5 to 0 h increased with the duration of isotope infusion, independent of tracer ( Fig. 2, Table 1 ). The mean isotopic enrichments (moles % excess) at steady state and the rates of isotope infusions of 13 C and 2 H 2 glucose in each of the four study protocols are provided in Table 1 . The calculated glucose R a 's are illustrated in Fig. 3 .
When both isotopes were infused for 2.5 h (protocol A), glucose R a (mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ) at steady state was similar for the two isotopes: 11.9 Ϯ 0. 13 C]glucose. The rate constants (k) of the isotopic enrichment decays after discontinuation of the isotope infusion and the t 1/2 of the isotopes are provided in Table  2 . Figure 4 depicts the isotopic enrichments after discontinuation of the infusion through the end of the study (expressed as percentage of the steady-state value), plasma glucose concentrations, and amount of tracer released into the plasma pool after glucagon administration. The decay (k ϭ rate constant ϫ 10
Ϫ3
) of the [1- 13 C]glucose tracer after a 2.5-h infusion (7.1 Ϯ 0.3) was similar (NS) to that after a 14.5-h infusion (6.4 Ϯ 0.2).
The decay of the [1-13 C]glucose tracer from the plasma pool after either 2.5 h or 14.5 h of infusion was slower (P Ͻ 0.05) than that of the [ Table 2) . Glucagon effect on glucose enrichment. There was no detectable tracer released from glycogen into the plasma pool during the 1 h after administration of glucagon (Fig. 4) 
DISCUSSION
The present studies demonstrate that glucose R a calculated during a 2.5-h primed constant rate infusion of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glucose was overestimated by 35% when compared with that calculated during a 14.5-h infusion of the same glucose tracer. This difference was 26% when the tracer used was [6,6-2 H 2 ]glucose. In theory, the overestimation could be due to 1) tracer recycling via glycogen ( 2 H 2 and 13 C) and/or Cori cycle ( 13 C) during the prolonged tracer infusion studies, 2) failure to achieve complete equilibration of the tracer with the tracee during the 2.5-h infusion, and 3) isotopic discrimination. From our data, we conclude that glycogen recycling of 13 C and 2 H glucose tracers are negligible even after a 14.5-h tracer infusion, whereas recycling, although small, of the 13 C glucose tracer via the Cori cycle was observed even with a 2.5-h tracer infusion. Because the glucose R a during simultaneous 2.5-h infusions of [1- 13 C]glucose and [6,6-2 H 2 ]glucose were essentially identical, isotope discrimination seems unlikely. Thus, failure to achieve complete equilibration of the tracer and tracee during the 2.5-h tracer infusion makes duration of isotope infusion an important factor that affects measures of glucose R a .
Although both the [1-13 C]glucose and [6,6-2 H 2 ]glucose tracers could theoretically recycle through glycogen via the direct pathway, only the carbon-labeled tracer can recycle back to glucose through the Cori cycle (3) (4) (5) 10) . In the present study, neither the [1-
13 C]glucose nor the [6,6-2 H 2 ]glucose tracer was released into the plasma glucose pool after glucagon infusion, making any significant recycling of tracer from glycogen unlikely. The [6,6-2 H 2 ]glucose tracer decay after 14.5 h or 5 h of infusion was slightly slower (ϳ10%) than that after the 2.5-h infusion. Because no detectable isotope decay curve change was observed after stimulation of glycogenolysis by glucagon infusion, it seems unlikely that this difference would be the result of release of tracer into the plasma space from glycogen. The decay of the [6,6-2 H 2 ]glucose tracer was faster than that of the [1-
13 C]glucose tracer independent of the duration of tracer infusion (Table 2) . However, unlike the [6,6-2 H 2 ]glucose tracer, the decays of the [1-
13 C]glucose tracer after 2.5-h or 14.5-h of infusion were similar (NS). This suggests an ongoing contribution of 13 C label from lactate to glucose during the decay period obscuring a small difference between the 2.5-and 14.5-h infusions as was observed with the [6,6-2 H 2 ]glucose tracer. Consistent with this speculation is that the higher lactate 13 C enrichment was almost twice as high during the prolonged compared with the short [1-
13 C]glucose infusion. Comparing the isotopic enrichment after the 14.5-h infusion of [6,6-2 H 2 ]glucose and [ 13 C]glucose indicates Cori cycle activities of ϳ10%. This is less than that of Reichard et al. (11) of 16% in normal subjects but greater than that estimated by Tayek et al. (12) of 5%.
Having excluded significant recycling of tracer via glycogen or the Cori cycle, we hypothesized that the 30% difference in glucose R a between the 2.5-and 14.5-h infusion was due to lack of complete equilibration of substrate and isotopes within the extracellular glucose space during the short (2.5 h) isotope infusion study. To test this hypothesis, we conducted protocol D using a 5-h infusion of [6,6-2 H 2 ]glucose. The glucose R a obtained after 5 h of tracer infusion was higher (P Ͻ 0.05) than that obtained after 14.5 h and lower (P Ͻ 0.05) than that observed after the 2.5-h infusion. Notably, extending the isotope infusion from 2.5 to 5 h reduced the overestimation of glucose R a by nearly 80%. A glucose tracer infused into the plasma pool needs to equilibrate with both the intravascular pool and the pool in the extracellularextravascular space, which is twice that of the intravascu- lar space. Thus, 2.5-h isotope infusion is not sufficient to achieve isotope and substrate equilibration in adults. In addition, this slowly equilibrating pool will complicate any attempt at non-steady-state modeling.
These conclusions in normal adult volunteers are supported by previous studies in patients with type 2 diabetes. In subjects with type 2 diabetes, hepatic glucose production was overestimated when the duration of a [3- 3 H]glucose infusion was insufficient for complete isotope equilibration, and the error was related to the degree of hyperglycemia (13) . Chen et al. (14) demonstrated that at least 4 h of tracer administration was necessary to reach steady state and accurately measure glucose R a in patients with type 2 diabetes but failed to observe this in normal subjects. They attributed this difference to the expanded plasma glucose pool size and the markedly reduced glucose uptake in the subjects with type 2 diabetes. Using a paired study design, we were able to demonstrate that this applies equally to normal individuals with normal plasma concentrations. Moreover, studies using prolonged isotope infusions in patients with type 2 diabetes could not confirm the increase in hepatic glucose production that was reported in some of the earlier studies using short (90 -120 min) infusion periods of [ 3 H]glucose (15, 16) . These observations are in agreement with the findings of the present study.
In this study, we used a 60-min priming dose of labeled glucose. We and others have used a variety of priming doses ranging from 60 to 100 min (17) (18) (19) . It is of interest that despite a 90-min prime in the study by Hovorka et al. (3) , the change in enrichment from a 120-to a 240-min time point was ϳ15%, which is nearly identical to the difference that we observed after infusion of isotope for 120 vs. 270 min, i.e., 13% (using a 60-min prime). In addition, these results are consistent with those of Hother-Nielsen et al. (20) . These investigators used 3 H glucose and provided data from normal control and type 2 diabetic subjects using a fixed prime or a prime adjusted to glycemia. In the normal control subjects, using a 100-min prime, the specific activity increased by 21% between 2.5 and 5 h of the isotope infusion as compared with 13% in our study (using a 60-min prime). In subjects with type 2 diabetes, the corresponding changes were 50% using a fixed 100-min prime and 25% using a prime adjusted to glycemia. Collectively, these results demonstrate that increasing the prime from 60 to 100 min did not overcome the isotopic disequilibrium in normal control subjects during short periods of isotope infusion. In subjects with type 2 diabetes, the use of an adjusted prime was helpful but did not completely overcome isotopic disequilibrium during short periods of isotope infusion. Thus, priming the substrate pool may be useful in approaching an "approximate" steady state during short infusions of glucose tracers but may still result in incomplete equilibration and an underestimation of glucose R a .
Erroneous measures of glucose R a will also result in propagating errors of measures of gluconeogenesis and glycogenolysis. The most recently described methods to measure gluconeogenesis ([U- 13 C]glucose [21, 22] and [2- 13 C]glycerol MIDA [23] ) and deuterated water with measurement of incorporation of deuterium in glucose carbons 5 and 6 (24) express gluconeogenesis as a fraction of glucose R a . Rates of gluconeogenesis are subsequently calculated as the product of fractional gluconeogenesis and glucose R a and, therefore, directly affected by an erroneous measure of glucose R a . Likewise, measures of glycogenolysis, which are calculated as the difference between glucose R a and the rate of gluconeogenesis, will also be affected. Similar errors may occur in studies using nuclear magnetic resonance (NMR). NMR provides an objective measure of glycogenolysis, whereas gluconeogenesis is calculated by subtracting glycogenolysis from glucose R a (measured by GCMS). In some reports using this NMR technique, short duration of tracer infusion was used to measure glucose R a (2-4 h) (25) (26) (27) . In these studies (despite using a prime dose corresponding to 100-min infusion), rates of glucose R a decreased from 12.6 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ⅐ day Ϫ1 at 2 h of isotope infusion to 8.4 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ⅐ day Ϫ1 after 4 h of infusion, i.e., 33%, which is in agreement with our results and reemphasizes the importance of using sufficient duration of isotope infusion.
These studies unequivocally demonstrate the importance of the duration of isotope infusion in achieving valid results. Thus, investigators who conduct studies on glucose turnover rates using tracer infusion periods of Ͻ4 -5 h should be cognizant that their measurements of glucose R a using steady-state equations may be overestimated, which has to be taken into account when drawing conclusions from their data.
